Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy.

ABSTRACT:

Background

Treatment options for many cancers include immune checkpoint inhibitor (ICI) monotherapy and combination therapy with impressive clinical benefit across cancers. We sought to define the comparative cardiac risks of ICI combination and monotherapy.

Methods

We used VigiBase, the World Health Organization pharmacovigilance database, to identify cardiac ADRs (cADRs), such as carditis, heart failure, arrhythmia, myocardial infarction, and valvular dysfunction, related to ICI therapy. To explore possible relationships, we used the reporting odds ratio (ROR) as a proxy of relative risk. A lower bound of a 95% confidence interval of ROR > 1 reflects a disproportionality signal that more ADRs are observed than expected due to chance.

Results

We found 2278 cADR for I

SUBMITTER: Cone EB 

PROVIDER: S-EPMC9624428 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature